Project Grant DP2AI192379
- This federal Project Grant award of $586,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research at the University of Massachusetts Medical School (UMass Medical) to investigate the generation and regulation of TFH13 cells that drive pathogenic IgE in allergic conditions. The overarching goal is to elucidate the pathways leading to TFH13 cell differentiation, which play a critical...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $164,108 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The project, titled "RNA Regulatory Circuits in Allergic Airway Inflammation," aims to identify RNA regulatory circuits that drive persistent type 2 inflammation in T cells and the airway epithelium in asthma patients. The research...
- This $175,000 federal Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the La Jolla Institute for Immunology. The funding supports research to explore the mechanisms and cell types that drive sensitization to the common airborne fungus Alternaria alternata and the development of asthma. The key products and services to be delivered include: 1) Assessing the role of a...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $250,000 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) for the project "Lung-Resident Memory TH2 Cells in Asthma: New Therapeutic Targets". The project aims to identify key pathways that mediate the survival and maintenance of Type 2 T helper (TH2) cells in the lungs of asthma...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $248,088 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University on January 12, 2025. The research aims to examine the role of immunoglobulin E (IgE) and the sugar-binding protein galectin-3 in the activation of basophils, which are immune cells involved in allergic reactions. Specifically, the project will compare galectin-3-dependent basophil activation...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, awarded a $414,368 Project Grant to the University of California, Davis. The grant supports research to characterize the impact of postnatal early-life exposure to house dust mite and ozone on the lung epigenome and explore the mechanistic link between these changes and alveolar development and airway remodeling. The project aims to leverage collected...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $180,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, College Park. The grant aims to develop a therapeutic approach using FC receptor-mediated delivery to treat airway inflammation and asthma. Preliminary research has shown that airway epithelial cells express FC receptors CD23 and FcRn, which can be leveraged to transport immune therapeutic...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $831,755 over 5 years to New York University (NYU) to conduct research on the role of lung-resident macrophage subsets in regulating type 2 immune responses and trained immunity. The research aims to elucidate the distinct functions of different macrophage populations, particularly nerve- and...
- This $197,366 Project Grant was awarded on March 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to identify the molecular mechanisms that control the natural, immune-mediated restriction of X4-tropic HIV virus, which typically emerges only in late-stage HIV disease when the immune system is impaired. The research will utilize primary CD4 T cells, in vivo analyses in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $238,972 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation for the State University of New York, doing business as Sponsored Projects Services, to study the role of the cellular protein EHD4 in restricting HIV-1 infection. The research aims to determine the mechanism by which EHD4 decreases the infectivity of HIV-1 particles by impacting the incorporation of...
The Project Grant award of $444,920 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund research by George Washington University to investigate the role of endogenous retroviruses in the development of type 2 immune responses that drive allergic inflammation in the lungs. The 5-year project aims to explore the downstream effects of HDM-induced ERV reactivation on type 2 allergic inflammation as well as the upstream epigenetic pathways that regulate ERV expression during allergic responses. The research will employ advanced techniques such as flow cytometry, cytokine/chemokine profiling, bulk and single-cell RNA sequencing, and ATAC-seq to elucidate these mechanisms in both in vitro and in vivo models. This award supports efforts to better understand the immunological triggers that initiate type 2 immunity in the context of pulmonary allergic diseases like asthma.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $444.9k | 8/25/25 |